Help

Search Results

2 results

  1. CORESTA Meeting, Smoke Science/Product Technology, 2021, Online, ST 45

    Meta-analysis study to establish population level estimates of NNAL in smokers and non-smokers

    AYALA-FIERRO F.(1); VERRON T.(2); LIZHNYAK P.(3); FREELAND R.(4); FROST-PINEDA K.(4); ELAMIN A.(5); PRASAD G.L.(4); SARKAR M.(3)
    (1) Juul Labs, Inc, U.S.A.; (2) Imperial Brands, U.K.; (3) Altria Client Services, U.S.A.; (4) RAI Services Company, U.S.A.; (5) Philips Morris International, Switzerland
    The purpose of this research (a project of the CORESTA Biomarkers Sub-Group) was to establish a population level estimate for the biomarker of cigarette smoke exposure, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL), to serve as a baseline...
  2. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, ST 45

    Meta-analysis of two biomarkers of exposure of tobacco products

    AYALA-FIERRO F.(1); ELAMIN A.(2); FROST-PINEDA K.(3); JIN T.(3); PRASAD G.L.(3); SARKAR M.(4); SCHMIDT E.(3); VERRON T.(5)
    (1) ITG Brands LLC, Greensboro, NC, U.S.A.; (2) PMI R&D, Philip Morris Products S.A., Neuchâtel, Switzerland; (3) RAI Services Company, Winston-Salem, NC, U.S.A.; (4) Altria Client Services LLC, Richmond, VA, U.S.A.; (5) SEITA - Imperial Brands, Paris, France
    In the context of tobacco products, broadly two types of biomarkers exist, biomarkers of exposure (BoE) and biomarkers of potential harm (BoPH). BoE measure exposure to tobacco constituents, e.g. carbon monoxide (CO) and nicotine equivalents (NEQs)....